^
Association details:
| Biomarker: | EGFR L858R + EGFR E709X + CTNNB1 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib
Published date:
12/15/2022
Excerpt:
The patient was diagnosed with lung adenocarcinoma...A genetic analysis of the primary tumor using the Oncomine Dx target test multi-CDx system revealed positivity for EGFR (L858R and E709X) and CTNNB1 mutations….The patient was treated with afatinib as first-line therapy and achieved clinical improvement and a partial response and is continuing treatment 1 year later.
DOI:
10.1111/1759-7714.14775
